ReviewInternational journal of molecular sciences2020
COVID-19: The Immune Responses and Clinical Therapy Candidates.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Pooled it
- Therapeutic Potential of Bioactive Compounds from Edible Mushrooms to Attenuate SARS-CoV-2 Infection and Some Complications of Coronavirus Disease (COVID-19).Journal of fungi (Basel, Switzerland) · 2023Review
- Nano-Enabled Antivirals for Overcoming Antibody Escaped Mutations Based SARS-CoV-2 Waves.International journal of molecular sciences · 2023Review
- Role and clinical implication of autophagy in COVID-19.Virology journal · 2023Review
- Kinetics of SuPAR hemoadsorption in critical COVID-19 patients on renal replacement therapy.BMC nephrology · 2022Observational
- Serum Levels of Proinflammatory Lipid Mediators and Specialized Proresolving Molecules Are Increased in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 and Correlate With Markers of the Adaptive Immune Response.The Journal of infectious diseases · 2022Article
- Risk Factors for Severity and Mortality in Adult Patients Confirmed with COVID-19 in Sierra Leone: A Retrospective Study.Infectious diseases & immunity · 2022Article
- COVID-19: cardiovascular manifestations-a review of the cardiac effects.Journal of geriatric cardiology : JGC · 2022Article
- Immunobiology and nanotherapeutics of severe acute respiratory syndrome 2 (SARS-CoV-2): a current update.Infectious diseases (London, England) · 2021Article
- A sensitive indicator for the severity of COVID-19: thiolTurkish journal of medical sciences · 2021Article
- An update to monoclonal antibody as therapeutic option against COVID-19.Biosafety and health · 2021Review
- Single-Cell Transcriptomic Profiling of MAIT Cells in Patients With COVID-19.Frontiers in immunology · 2021Article
- A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19.Frontiers in public health · 2021Article
- Point of Care Diagnostics in the Age of COVID-19.Diagnostics (Basel, Switzerland) · 2020Review
- Cell-mediated immunity to SARS-CoV-2.Pediatric investigation · 2020Review
- Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID-19.Clinical and translational medicine · 2020Article
- Arrhythmia in COVID-19.SN comprehensive clinical medicine · 2020Review
- The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pandemic of coronavirus disease 2019 (COVID-19), with rising numbers of patients worldwide, presents an urgent need for effective treatments. To date, there are no therapies or vaccines that are proven to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several potential candidates or repurposed drugs are under investigation, including drugs that inhibit SARS-CoV-2 replication and block infection. The most promising therapy to date is remdesivir, which is US Food and Drug Administration (FDA) approved for emergency use in adults and children hospitalized with severe suspected or laboratory-confirmed COVID-19. Herein we summarize the general features of SARS-CoV-2's molecular and immune pathogenesis and discuss available pharmacological strategies, based on our present understanding of SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) infections. Finally, we outline clinical trials currently in progress to investigate the efficacy of potential therapies for COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.